BCM
ALXN

Beryl Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Beryl Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-553,245
Closed -$102M – 286
2021
Q2 		$102M Buy
+553,245
New +$95M 9.07% 1

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Beryl Capital Management's ALXN Position: Q3 2021 in Review

Beryl Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 553,245 shares — an estimated $102M sold.

Beryl Capital Management first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $102M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Beryl Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Beryl Capital Management sold 553,245 Alexion Pharmaceuticals shares in Q3 2021, an estimated $102M.
  • Beryl Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Beryl Capital Management's Alexion Pharmaceuticals position peaked at $102M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Beryl Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.